Living

Merck's bowel disease drug meets main goal in late-stage trial

By Reuters Reuters
The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid
The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid BRENDAN MCDERMID Reuters

Merck said on Monday its drug met the main goal in a late-stage trial testing it in patients with a type of inflammatory bowel disease.

(Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 22, 2026 at 6:16 AM.

Get unlimited digital access
#ReadLocal

Try 1 month for $1

CLAIM OFFER